Lupin gets tentative USFDA nod for type 2 diabetes drug

Empagliflozin and Metformin Hydrochloride Extended Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg

175
Medicine Tablet
Picture: Pixabay

Last Updated on January 9, 2021 by The Health Master

Lupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from the United States Food and Drug Administration (USFDA).

This approval is to market a generic equivalent of Synjardy XR Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

The product will be manufactured at Lupin’s Nagpur facility in India.


Also read | Lupin gets USFDA approval for bacterial infection drug


Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate.

Empagliflozin and Metformin Hydrochloride ER Tablets (RLD: Synjardy XR) had estimated annual sales of $357 million in the US. (IQVIA MAT November 2020).


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here